ACKNOWLEDGMENTS

The Editorial Board of *Clinical Science* gratefully acknowledges the assistance given by the following referees during the year 1995.

Abernathy, D.
Agardh, E.
Agrotis, A.
Aitkenhead, A.R.
Ali, N.
Andersen, D.
Anderson, S.
Andrews, F.
Angelin, B.
Araki, S.
Archer, L.
Aronberg, S.
Andrews, F.
Angelin, B.
Ardawi, M.S.M.
Arieff, A.I.
Armstrong, V.W.
Arnold, J.M.O.
Amqvist, H.
Arslanian, S.
Arthur, J.
Astarie Dequecker, C.
Bailey, R.R.
Baines, A.
Bankir, L.
Banks, R.
Barclay, R.
Baron, A.D.
Barradas, M.A.
Barrett, E.J.
Barton, H.
Bassey, J.E.
Batchelard, H.
Beaudouin-Legros, M.
Beavan, L.
Beckett, G.
Bell, J.
Belpaire, F.
Benjamin, N.
Bennett, A.
Berl, T.
Berne, C.
Besley, G.
Best, J.
Beynon, H.
Bharaj, H.S.
Bhatnagar, D.
Bie, P.
Bishop, J.
Bistrian, B.R.
Black, C.
Blomberg, P.
Bobik, A.
Boer, W.H.
Bolter, C.P.
Bonham, J.
Bolton, C.
Boot-Handford, R.
Boughton-Smith, N.K.
Boulanger, C.
Bowyer, D.E.
Bould, K.
Brands, M.
Brasseur, D.
Breyer, M.D.
Bringhurst, F.R.
Brown, KE.
Brown, M.A.
Bryer-Ash, M.
Bund, S.
Burkett, K.
Burdon, R.H.
Burgess, A.W.
Burrell, L.M.
Calder, P.C.
Calver, A.
Campbell, N.E.
Caprio, S.
Carlson, M.G.
Caro, C.G.
Casadei, B.
Casolaro, A.
Charles, C.
Chau, N.P.
Cheek, N.
Cherrington, A.
Ch'ng, J.L.C.
Chow, P.J.
Chung, K.F.
Clapp, J.
Clarke, C.
Clavey, V.
Clayton, P.
Cleland, J.
Clement, D.L.
Cline, G.
Cockcroft, J.R.
Cole, A.T.
Collins, A.
Collins, P.
Cooke, J.P.
Ctalk, B.
Crouch, M.
Cruickshank, J.K.
Cuspidi, C.
Dantzer, D.
Dart, T.
Davidson, N.
Davies, D.
Davies, M.
Dausse, J.P.
Day, C.P.
De Backer, G.
Deegan, P.C.
de Jong, N.
de Leeuw, P.W.
de Rijke, Y.B.
de Vernejoul, M.C.
Deutz, N.
Dimsdale, J.E.
Dockray, G.J.
Donker, A.J.M.
Donnelly, S.
Doorly, D.
Dornhurst, A.
Dowling, D.
Dransfield, I.
Drejer, K.A.
Dryden, S.
Dullaert, R.P.F.
Duprez, D.
During, M.
Duthie, G.
Edelman, A.
Edelson, G.
Ec, H.
Elahi, D.
Elia, M.
Emery, P.W.
Emmerich, J.
Enholm, C.
Erikson, E.F.
Eriksson, U.
Escourrou, P.
Esler, M.D.
Espiner, E.A.
Evans, B.
Fallen, E.
Fearon, K.
Feizi, T.
Feldman, R.
Feray, J.C.
Ferguson, A.
Fernig, D.
Ferrari, A.U.
Ferrari, M.D.
Feuvray, D.
Fitchett, D.
Ford, G.A.
Forster, C.
Forsling, M.
Forte, L.R.
Fosang, A.
Franceschini, G.
Frayn, K.N.
Freeman, D.
Freestone, S.
Frelin, C.
Friedman, P.
Fryburg, D.
Fuller, B.J.
Furst, P.
Garlick, P.
Gaultier, C.
Gefland, R.A.
Gellai, M.
Gibson, P.
Gilchrist, N.L.
Goode, G.K.
Goodlad, R.
Gore, M.
Gosden, C.M.
Goto, K.
Grassi, G.
Green, A.
Green, C.J.
Griffiths, R.
Griffiths, T.M.
Grime, G.
Grinn, M.
Groop, L.
Grubeck-Loebenstein, B.
Haddad, F.
Hales, C.
Hales, J.
Hall, M.J.
Halliday, D.
Hans, G.
Hansen, P.R.
Hanson, U.
Harding, J.J.
Harris, K.
Head, G.A.
Heagerty, A.M.
Helft, G.
Henderson, I.S.
Hill, J.
Hjermindahl, P.
Holder, D.S.
Horne, P.D.
Hothrer Nielsen, O.
Hughes, A.
Hughes, P.
Hughson, R.
Huisman, R.M.
Hulcanchtz, R.
Hunter, J.
Ikeda, U.
Iramo, H.
Imaiizumi, T.
Ind, P.
Iouzalen, L.
Iredale, J.P.
Jack, C.I.A.
Jackson, M.J.
Jain, B.
Jaken, P.M.
Janssen, W.M.T.
Jenkinson, S.
Jennings, G.L.
Jensen, M.
Johnson, M.R.
Johnston, P.W.
Johnstone, F.
Jones, D.
Jones, M.
Jover, B.
Julius, S.
Kamen, P.
Kaplan, A.
Khan, F.
Kingsnorth, A.N.
Kingswell, B.
Kinnear, W.
Klein, G.
Knox, A.
Kostad, F.
Koomans, H.A.
Kopp, U.
Korner, P.
Kostuk, W.
Krediel, R.Th.
<table>
<thead>
<tr>
<th>Author</th>
<th>Pages</th>
</tr>
</thead>
<tbody>
<tr>
<td>Abdel-Meguid, E.</td>
<td>187–191</td>
</tr>
<tr>
<td>Abdel-Tawab, S.</td>
<td>187–191</td>
</tr>
<tr>
<td>Abu-Amsha, R.</td>
<td>449–458</td>
</tr>
<tr>
<td>Aguilerá, M.T.</td>
<td>155–161</td>
</tr>
<tr>
<td>Ainley, C.</td>
<td>219–223</td>
</tr>
<tr>
<td>Albert, J.</td>
<td>225–231</td>
</tr>
<tr>
<td>Allan, P.L.</td>
<td>17–21</td>
</tr>
<tr>
<td>Almada, A.L.</td>
<td>113–118</td>
</tr>
<tr>
<td>Amadi, A.A.</td>
<td>391–398</td>
</tr>
<tr>
<td>Andersen, S.E.</td>
<td>99–106</td>
</tr>
<tr>
<td>Armstrong, A.L.</td>
<td>685–690</td>
</tr>
<tr>
<td>Arthur, J.R.</td>
<td>107–111</td>
</tr>
<tr>
<td>Atucha, N.M.</td>
<td>733–738</td>
</tr>
<tr>
<td>Baker, G.</td>
<td>51–58</td>
</tr>
<tr>
<td>Barbara, L.</td>
<td>219–223</td>
</tr>
<tr>
<td>Barden, A.</td>
<td>711–718</td>
</tr>
<tr>
<td>Bassey, E.J.</td>
<td>685–690</td>
</tr>
<tr>
<td>Belch, J.F.F.</td>
<td>17–21</td>
</tr>
<tr>
<td>Bell, S.C.</td>
<td>169–175</td>
</tr>
<tr>
<td>Benn, J.</td>
<td>575–582</td>
</tr>
<tr>
<td>Bernard, C.</td>
<td>29–33</td>
</tr>
<tr>
<td>Bernardi, L.</td>
<td>35–43</td>
</tr>
<tr>
<td>Bianchetti, M.G.</td>
<td>347–351</td>
</tr>
<tr>
<td>Binah, O.</td>
<td>233–239</td>
</tr>
<tr>
<td>Blakemore, S.J.</td>
<td>591–599</td>
</tr>
<tr>
<td>Bongso, A.</td>
<td>248–249</td>
</tr>
<tr>
<td>Bourgin, P.</td>
<td>45–50</td>
</tr>
<tr>
<td>Bradford, A.</td>
<td>337–345</td>
</tr>
<tr>
<td>Bragado, M.J.</td>
<td>365–369, 771</td>
</tr>
<tr>
<td>Bragulat, E.</td>
<td>155–161</td>
</tr>
<tr>
<td>Bränström, R.</td>
<td>431–439</td>
</tr>
<tr>
<td>Bröijersén, A.</td>
<td>225–231</td>
</tr>
<tr>
<td>Brown, K.M.</td>
<td>107–111</td>
</tr>
<tr>
<td>Browne, G.</td>
<td>79–86</td>
</tr>
<tr>
<td>Brundin, T.</td>
<td>431–439</td>
</tr>
<tr>
<td>Bund, S.J.</td>
<td>739–743</td>
</tr>
<tr>
<td>Buvry, A.</td>
<td>319–327</td>
</tr>
<tr>
<td>Cacchifesta, A.M.</td>
<td>385–389</td>
</tr>
<tr>
<td>Cailmail, S.</td>
<td>29–33</td>
</tr>
<tr>
<td>Calverley, P.M.A.</td>
<td>513–518</td>
</tr>
<tr>
<td>Calvo, J.J.</td>
<td>365–369, 771</td>
</tr>
<tr>
<td>Campbell, B.J.</td>
<td>359–364</td>
</tr>
<tr>
<td>Canali, C.</td>
<td>275–281</td>
</tr>
<tr>
<td>Carter, J.</td>
<td>513–518</td>
</tr>
<tr>
<td>Cartouzou, G.</td>
<td>209–212</td>
</tr>
<tr>
<td>Carver, J.G.</td>
<td>725–731</td>
</tr>
<tr>
<td>Caso, G.</td>
<td>99–106</td>
</tr>
<tr>
<td>Cassell, T.B.</td>
<td>509–512</td>
</tr>
<tr>
<td>Castleden, C.M.</td>
<td>467–474</td>
</tr>
<tr>
<td>Cattell, V.</td>
<td>375–384</td>
</tr>
<tr>
<td>Celli, V.</td>
<td>385–389</td>
</tr>
<tr>
<td>Cester, N.</td>
<td>719–723</td>
</tr>
<tr>
<td>Chadwick, I.G.</td>
<td>617–620</td>
</tr>
<tr>
<td>Chan, S.H.</td>
<td>256–258</td>
</tr>
<tr>
<td>Chan, S.Y.</td>
<td>250–252</td>
</tr>
<tr>
<td>Charles, C.J.</td>
<td>283–291</td>
</tr>
<tr>
<td>Chin-Dusting, J.</td>
<td>23–28</td>
</tr>
<tr>
<td>Christensen, N.J.</td>
<td>621–626</td>
</tr>
<tr>
<td>Chu, T.P.</td>
<td>391–398</td>
</tr>
<tr>
<td>Cipollina, M.R.</td>
<td>703–710</td>
</tr>
<tr>
<td>Claassen, J.A.H.R.</td>
<td>483–488</td>
</tr>
<tr>
<td>Clague, J.E.</td>
<td>513–518</td>
</tr>
<tr>
<td>Clark, M.L.</td>
<td>425–430</td>
</tr>
<tr>
<td>Coats, A.J.S.</td>
<td>391–398</td>
</tr>
<tr>
<td>Coca, A.</td>
<td>155–161</td>
</tr>
<tr>
<td>Colombani, V.</td>
<td>209–212</td>
</tr>
<tr>
<td>Colombo, R.</td>
<td>391–398</td>
</tr>
<tr>
<td>Compton, J.E.</td>
<td>307–312</td>
</tr>
<tr>
<td>Connell, J.M.C.</td>
<td>65–71</td>
</tr>
<tr>
<td>Cook, H.T.</td>
<td>375–384</td>
</tr>
<tr>
<td>Coupland, C.A.C.</td>
<td>685–690</td>
</tr>
<tr>
<td>Cowley, A.J.</td>
<td>415–423</td>
</tr>
<tr>
<td>Crawley, J.</td>
<td>51–58</td>
</tr>
<tr>
<td>Crijns, F.R.L.</td>
<td>131–139</td>
</tr>
<tr>
<td>Critchley, J.A.H.</td>
<td>35–43</td>
</tr>
<tr>
<td>Croft, K.D.</td>
<td>449–458, 711–718</td>
</tr>
<tr>
<td>Curran, A.K.</td>
<td>337–345</td>
</tr>
<tr>
<td>D'Almeida, M.</td>
<td>29–33</td>
</tr>
<tr>
<td>Davies, P.S.W.</td>
<td>763–769</td>
</tr>
<tr>
<td>Day, J.M.E.</td>
<td>763–769</td>
</tr>
<tr>
<td>de Silva, H.A.</td>
<td>725–731</td>
</tr>
<tr>
<td>de Chazal, R.</td>
<td>169–175</td>
</tr>
<tr>
<td>De La Sierra, A.</td>
<td>155–161</td>
</tr>
<tr>
<td>De Leeuw, P.W.</td>
<td>163–168</td>
</tr>
<tr>
<td>De Propris, A.M.</td>
<td>385–389</td>
</tr>
<tr>
<td>De Rooij, M.J.M.</td>
<td>483–488</td>
</tr>
<tr>
<td>Del Mar Lluch, M.</td>
<td>155–161</td>
</tr>
<tr>
<td>Dessauer, C.W.</td>
<td>527–537</td>
</tr>
<tr>
<td>Di Bernardo, M.G.</td>
<td>385–389</td>
</tr>
<tr>
<td>Di Virgilio, F.</td>
<td>703–710</td>
</tr>
<tr>
<td>Dickinson, C.J.</td>
<td>539–550</td>
</tr>
<tr>
<td>Dimitriadou, V.</td>
<td>319–327</td>
</tr>
<tr>
<td>Ding, X.-J.</td>
<td>93–98</td>
</tr>
<tr>
<td>Dowling, R.H.</td>
<td>509–512</td>
</tr>
<tr>
<td>Drummond, P.D.</td>
<td>73–77</td>
</tr>
<tr>
<td>Dudley, F.</td>
<td>23–28</td>
</tr>
<tr>
<td>Duner, E.</td>
<td>703–710</td>
</tr>
<tr>
<td>Duthie, G.G.</td>
<td>107–111</td>
</tr>
<tr>
<td>Dutto, F.</td>
<td>313–318</td>
</tr>
<tr>
<td>Earnest, C.P.</td>
<td>113–118</td>
</tr>
<tr>
<td>El-Gamal, N.</td>
<td>627–631</td>
</tr>
<tr>
<td>Elliott, H.L.</td>
<td>65–71</td>
</tr>
<tr>
<td>Elliott, R.A.</td>
<td>467–474</td>
</tr>
<tr>
<td>Ellory, J.C.</td>
<td>353–358</td>
</tr>
<tr>
<td>Engelman, J.L.</td>
<td>509–512</td>
</tr>
<tr>
<td>Escourrou, P.</td>
<td>45–50</td>
</tr>
<tr>
<td>Espiner, E.A.</td>
<td>283–291</td>
</tr>
<tr>
<td>Essén, P.</td>
<td>99–106</td>
</tr>
<tr>
<td>Eto, T.</td>
<td>293–298</td>
</tr>
<tr>
<td>Fagbemi, O.S.</td>
<td>745–754</td>
</tr>
<tr>
<td>Farag, M.M.</td>
<td>187–191</td>
</tr>
<tr>
<td>Farmer, R.D.T.</td>
<td>87–92</td>
</tr>
<tr>
<td>Farzanef, F.</td>
<td>213–218</td>
</tr>
<tr>
<td>Feigel, P.</td>
<td>45–50</td>
</tr>
<tr>
<td>Felzen, B.</td>
<td>233–239</td>
</tr>
<tr>
<td>Feng, Y.-H.</td>
<td>459–466</td>
</tr>
<tr>
<td>Finch, P.M.</td>
<td>73–77</td>
</tr>
<tr>
<td>Finnie, I.A.</td>
<td>359–364</td>
</tr>
<tr>
<td>Flanagan, G.J.</td>
<td>353–358</td>
</tr>
<tr>
<td>Forster, C.D.</td>
<td>425–430</td>
</tr>
<tr>
<td>Fortepiani, L.A.</td>
<td>733–738</td>
</tr>
<tr>
<td>Fowler, B.</td>
<td>79–86</td>
</tr>
<tr>
<td>Franks, S.M.</td>
<td>627–631</td>
</tr>
<tr>
<td>Frayn, K.N.</td>
<td>425–430, 679–683</td>
</tr>
<tr>
<td>Freestone, S.</td>
<td>177–185</td>
</tr>
<tr>
<td>Frick, G.</td>
<td>79–86</td>
</tr>
<tr>
<td>Frossard, N.</td>
<td>319–327</td>
</tr>
<tr>
<td>Frostell, C.</td>
<td>225–231</td>
</tr>
<tr>
<td>Gafer, U.</td>
<td>519–523</td>
</tr>
<tr>
<td>Garbarg, M.</td>
<td>319–327</td>
</tr>
<tr>
<td>Garcia, L.J.</td>
<td>365–369, 771</td>
</tr>
<tr>
<td>Garcia-Estanj, J.</td>
<td>733–738</td>
</tr>
<tr>
<td>Garlick, P.J.</td>
<td>99–106</td>
</tr>
<tr>
<td>Gaskin, G.</td>
<td>329–335</td>
</tr>
<tr>
<td>Gerolami, A.</td>
<td>209–212</td>
</tr>
<tr>
<td>Ghosh, S.</td>
<td>213–218</td>
</tr>
<tr>
<td>Gibson, A.</td>
<td>633–638</td>
</tr>
<tr>
<td>Gilman, A.G.</td>
<td>527–537</td>
</tr>
<tr>
<td>Giner, V.</td>
<td>155–161</td>
</tr>
<tr>
<td>Giordano, A.</td>
<td>391–398</td>
</tr>
<tr>
<td>Glenville, B.</td>
<td>51–58</td>
</tr>
<tr>
<td>Goldman, J.M.</td>
<td>329–335</td>
</tr>
</tbody>
</table>
Goldstein, D. 233–239
González, A. 365–369, 771
Goodlad, R.A. 503–507
Granger, J.P. 497–502
Green, C. 307–312
Griffin, G.E. 241–245
Grimble, R.F. 121–130
Gusmaroli, R. 219–223
Gustafsson, F. 621–626
Haefeli, W.E. 79–86
Hafen, G. 347–351
Hansen, J.M. 489–496
Harrington, D. 391–398
Hart, G. 459–466
Heagerty, A.M. 739–743
Heude, E. 45–50
Hider, R. 633–638
Higgins, K.S. 617–620
Hillis, G.S. 639–650
Hjemdahl, P. 225–231
Hodgson, H.J. 329–335
Holton, J. 219–223
Hong, C.Y. 601–606
Hoskins, P.R. 17–21
Houben, A.J.H.M. 163–168
Huang, Y.-T. 601–606
Huang, Y.W. 93–98
Hughes, J.M.B. 329–335
Humphreys, S.M. 425–430, 679–683
Hundal, H.S. 591–599
Hutton, I. 739–743
Idone, G. 385–389
Imholz, B.P.M. 193–200
Ishikawa, T. 755–761
Ishimitsu, T. 293–298
Jackson, A.A. 607–615
Jackson, P.R. 399–413, 617–620, 773–774
James, M.A. 59–64
Janssen, M.C.H. 483–488
Jebb, S.A. 241–245
Jellema, W.T. 193–200
Jennings, G. 23–28, 241–245
Ji, M.R. 93–98
Johnston, N.R. 177–185
Jones, D.E.J. 551–558
Jones, P.H. 141–146
Kakkar, R. 441–448
Kalechman, Y. 519–523
Kalra, J. 441–448
Kamen, P.W. 201–208
Kang, J.Y. 252–254
Kangawa, K. 293–298
Karet, F.E. 267–273
Kay, R.L.C. 35–43
Kearney, M.T. 415–423
Kemp, G.J. 691–702
Kersten, A.H. 475–481
Kime, R. 633–638
Kirchner, K.A. 497–502
Kirstetter, P. 29–33
Kitamura, K. 293–298
Knudsen, J.H. 621–626
Konje, J.C. 169–175
Kosoglou, T. 283–291
Krasikiewicz, M. 617–620
Krum, H. 201–208
Kurashina, T. 497–502
Kabiri, A. 51–58
Lainchbury, J.G. 3–16, 525
Langley-Evans, S.C. 607–615
Laux-End, R. 347–351
Lawson, K. 651–663
Lee, K.O. 254–256
Lee, M.R. 177–185
Lerique, B. 209–212
Leyssac, P.P. 489–496
Li, X.C. 147–154
Li Kam Wa, T.C. 177–185
Ligtenberg, J.J.M. 583–589
Lin, H.-C. 601–606
Liu, T.-B. 601–606
Liu, T.-B. 601–606
Lo, T.W.C. 575–582
López, M.A. 356–369, 771
Lotan, R. 233–239
Lucarelli, G. 719–723
Lutterman, J.A. 539–546
Lwakire, P.M. 559–565
L'Her, J.M. 415–423, 425–430
Macarthur, R.F. 219–223
MacLeod, A.M. 639–650
Macpherson, M.B. 685–690
Mantha, S.V. 599–606
Marangella, M. 313–318
Marinello, G. 385–389
Martínez, C. 733–738
Matsuo, H. 293–298
Matsuoka, H. 293–298
May, H. 307–312
Mazzanti, L. 719–723
Mazzuero, G. 391–398
McGuigan, J.A.S. 347–351
McKie, A.T. 213–218
McLellan, A.C. 575–582
McNally, P.G. 59–64
McNurlan, M.A. 99–106
Menegatti, M. 219–223
Menys, V.C. 87–92
Michael, C.A. 711–718
Miglioli, M. 219–223
Mikhail, M. 187–191
Millar, J.A. 567–573
Milton, J.D. 359–364
Minami, J.-I. 293–298
Mione, V. 275–281
Miranda, F. 219–223
Mitchell, T.L. 113–118
Moreau, R. 29–33
Mormino, P. 275–281
Morrice, P.C. 107–111
Morris, A.D. 65–71
Morris, R.J. 679–683
Morton, J.J. 169–175
Murphy, G.M. 509–512
Murphy, S. 307–312
Netten, P.M. 559–565
Newlands, G.F.J. 319–327
Ng, S.C. 254–256
Nicholls, M.G. 3–16, 283–291, 525
Nicolosi, G. 275–281
Nishikimi, T. 293–298
Nishino, T. 755–761
Noble, M.I.M. 87–92
Nocco, M.L. 385–389
Norman, R.I. 467–474
Northover, B.J. 745–754
Nosophin, R. 703–710
O'Brien, S.F. 567–573
Oh, Y.M.S. 247, 261–264
Oldroyd, B. 763–769
Olsen, N.V. 489–496
Ortiz, M.C. 733–738
Palatini, P. 275–281
Panerai, R. 59–64
Parker, S.G. 467–474
Patek, G. 497–502
Payne, J.N. 399–413, 773–774
Author Index

Pearson, M.G. 513-518
Peeters, L.L.H. 163-168
Peheim, E. 347-351
Pereira, S.P. 509-512
Peters, A.M. 275-281
Peters, T.J. 213-218
Petrarulo, M. 313-318
Petrie, J.R. 739-743
Pickin, D.M. 399-413, 773-774
Piepoli, M. 391-398
Piao, K. 359-364
Powers, H. 633-638
Prasad, K. 441-448
Primrose, J.N. 371-374
Proudfoot, J.M. 449-458
Qureshi, I.A. 93-98
Rabini, R.A. 719-723
Radda, G.K. 691-702
Rae, C. 353-358
Raja, S.N. 627-631
Ramsay, L.E. 399-413, 617-620, 773-774
Ravel, U. 51-58
Recchi, D. 385-389
Reitsma, W.D. 583-589
Ren, E.C. 256-258
Rennie, M.J. 591-599
Rhodes, J.M. 359-364
Ricci, C. 219-223
Richards, A.M. 3-16, 283-291, 525
Ricks, D.K. 591-599
Ritchie, J. 711-718
Rooyackers, O.E. 475-481
Rouleau, A. 319-327
Rovera, L. 313-318
Ryan, J. 23-28
Sadik, S.K. 359-364
Savill, J. 329-335
Schibler, A. 347-351
Schwartz, J.-C. 319-327
Scully, A. 385-389
Selldén, E. 431-439
Shan, Y.-F. 93-98
Shehata, R. 187-191
Sherman, R.C. 607-615
Shirley, D.G. 299-305
Shore, C. 51-58
Silvester, W. 567-573
Silvanà, V. 209-212
Simpson, E.J. 425-430
Simpson, R.J. 213-218
Skipworth, S. 73-77
Sladen, G.E. 509-512
Slutier, W.J. 583-589
Smith, A.J. 583-589
Smith, C.C.T. 87-92
Smith, M.A. 763-769
Sönksen, P.H. 575-582
Soupison, T. 29-33
Sredni, B. 519-523
Staffolani, R. 719-723
Stolte, J. 131-139
Stonebridge, P.A. 17-21
Stritoni, P. 275-281
Struijker-Boudier, H.A.J. 131-139
Stubbs, T.A. 415-423
Sugimori, K. 755-761
Summers, L.K.M. 679-683
Swales, A.D. 59-64
Tan, C.-C. 258-260
Tavakoli, R. 319-327
Tay, A. 264-266
Taylor, B.A. 359-364
Taylor, D.J. 169-175
Taylor, E.A. 261-264
Teds, A. 29-33
Thien, Th. 483-488, 559-565
Thompson, C.H. 691-702
Thorell, A. 99-106
Thorvald, P.J. 575-582
Thorniley, M.S. 51-58
Thurston, H. 59-64
Tjäder, I. 99-106
Toft, J. 621-626
Tomlinson, B. 35-43
Tong, A.M. 201-208
Trevisan, M. 703-710
Trevisan, R. 703-710
Truttmann, A.C. 347-351
Tsai, J.-F. 601-606
Turner, J.M. 763-769
Ueda, S. 65-71
Ullah, I. 399-413, 773-774
Unwin, R.J. 299-305
Urbano-Márquez, A. 155-161
Usov, V. 329-335
Vaira, D. 219-223
Van Asten, W.N.J.C. 483-488
Van Beck, E. 163-168
Van der Kolk, L.E. 583-589
Van Es, P.N. 163-168
Van Essen, H. 131-139
Van Gouw, V. 193-200
Van Lieshout, J.J. 193-200
Visentini, P. 275-281
Vitale, C. 313-318
Volkert, M. 391-398
Wagenmakers, A.J.M. 475-481
Wallace, W.A. 685-690
Wallen, N.H. 225-231
Walter, S.J. 299-305
Walters, B.N. 711-718
Watt, P.W. 591-599
Watts, G.F. 567-573
Webster, N. 371-374
Welham, S.J.M. 607-615
Wernerman, J. 99-106
Wesseling, K.H. 193-200
Weston, P.J. 59-64
Whitaker, R.P. 467-474
Widdop, R.E. 147-154
Willake, C. 163-168
Winearls, C.G. 353-358
Wollersheim, H. 483-488, 559-565
Woo, S. 35-43
Woodrow, G. 763-769
Wu, P.K. 627-631
Xie, Y. 93-98
Yang, M.C.-M. 601-606
Yang, S. 29-33
Yeo, W.W. 399-413, 617-620, 773-774
Yeung, D.T.K. 35-43
Yeung, D.Y.C. 35-43
Young, R. 307-312
Yu, L.-G. 359-364
Zolese, G. 719-723
Accidental falls oestrogen replacement therapy 685–690
Acetylcholine
endothelium, Syndrome X 739–743
nitric oxide, liver cirrhosis 733–738
Action potential cardiac muscle, nutritional iron deficiency 233–239
Activation energy
Na+, K+-ATPase, gestational hypertension 719–723
S-Adenosylhomocysteine metabolism 79–86
S-Adenosylmethionine metabolism 79–86
Adenylate cyclase
G-proteins, signal transduction 527–537*
Adipose tissue
microdialysis, catecholamines 425–430
Adipose tissue blood flow
body mass index 679–683
Adrenaline
lymphocytes, cyclic AMP 612–626
α-Adrenergic receptors
skin, reflex sympathetic dystrophy 73–77
Adrenergic β-receptors
lymphocytes, noradrenaline 621–626
α-Adrenoceptor antagonist
thermoregulation 627–631
Adrenomedullin
G-protein-linked receptors, cyclic AMP 3–16*, 525
salt, essential hypertension 293–298
Ageing
lymphocytes, cyclic AMP 621–626
Alcohol
pancreatitis-associated protein
messenger RNA 213–218
Alcoholic cirrhosis
nitric oxide 23–28
Aliphatic amines
renal failure, choline transport 353–358
Alkalosis
hyperventilation, magnesium 347–351
Almitrine
ventilation, muscle activity 337–345
Ambulatory blood pressure
left ventricular function, hypertension 275–281
Ambulatory monitoring
blood pressure, sleep 45–50
Amino acids
inflammation, cytokines 121–130*
metabolism, vascular disease 79–86
renal transplant recipients,
cyclosporin A 489–496
thermogenesis, anaesthesia 431–439
Aminoglycosides
nephrotoxicity, non-steroidal anti-inflammatory drugs 187–191
Amylase release
pancreatitis 365–369, 771
Anaesthesia
amino acids, thermogenesis 431–439
Angina
cholesterol, lipids 399–413, 773–774
Angiotensin II
microalbuminuria, non-insulin-dependent diabetes 703–710
Angiotensin type 1 receptor antagonists
renal vasodilatation, spontaneously hypertensive rats 147–154
Angiotensin-converting enzyme
 genetic polymorphism, bradykinin 617–620
Antioxidant enzyme
vitamin E, smoking 107–111
Antioxidants
inflammation, cytokines 121–130*
Antisense oligodeoxynucleotides
multidrug resistance 93–98
Aorta
nitric oxide, liver cirrhosis 733–738
Arachidonic acid
phospholipids, Crohn’s disease 509–512
Arterialization
insulin sensitivity, forearm blood flow 65–71
Artery
morphology, syndrome X 739–743
ATP synthesis
Subject Index

exercise, obesity 691–702
ATP-sensitive potassium channels
potassium channel openers 651–663*
Atrial natriuretic peptide
neutral endopeptidase, ventricular pacing 283–291
salt, essential hypertension 293–298
potassium channel openers 651–663*
Autoantigen
T-lymphocytes, biliary cirrhosis 551–558
Autoimmunity
T-lymphocytes, biliary cirrhosis 551–558
Autonomic function
baroreflex sensitivity, insulin-dependent diabetes mellitus 59–64
Autonomic nervous system
heart failure, heart rate variability 391–398
heart failure, spectral power 35–43
Poincaré plot, heart rate variability 201–208
Autoregulation
Na+, K+-ATPase, ouabain 497–502
Balance
oestrogen replacement therapy 685–690
Baroreflex sensitivity
autonomic function, insulin-dependent diabetes mellitus 59–64
Bicarbonate-urea method
energy expenditure, human immunodeficiency virus infection 241–245
Biliary cirrhosis
autoimmunity, T-lymphocytes 551–558
Blastocyst transfer
human embryos 248–249
Bleeding time
inhaled nitric oxide 225–231
Blood flow
vascular disease, ultrasound 17–21
Blood pressure
ambulatory monitoring, sleep 45–50
stroke volume, syncope 193–200
Blood temperature
amino acids, anaesthesia 431–439
Blood transfusion
T-helper 2 cytokines, transforming growth factor 519–523
Body composition
chronic kidney failure 763–769
Body mass index
adipose tissue blood flow 679–683
Bone mineral density
postmenopausal women 307–312
Bone resorption
calcium nephrolithiasis, mineral water 313–318
Bradykinin
angiotensin-converting enzyme, genetic polymorphism 617–620
endothelium, Syndrome X 739–743
Brain
oxidative metabolism, hypertension 539–550
Brain natriuretic peptide
neutral endopeptidase, ventricular pacing 283–291
Breath-holding time
development of breathing, dyspnoea 755–761
Bronchial hyper-responsiveness
lung transplantation, mast cells 319–327
Bumetanide
Na+/K+/2Cl− co-transport 725–731
Caerulein
pancreatitis, intracellular calcium 365–369, 771
Caffeic acid
lipoprotein oxidation, wine 449–458
Calcium
alkalosis, hyperventilation 347–351
Calcium antagonist
oxidents 459–466
urinary bladder 467–474
Calcium nephrolithiasis
mineral water 313–318
Calcium oxalate
urine state of saturation, calcium nephrolithiasis 313–318
Calcium phosphate
urine state of saturation, calcium nephrolithiasis 313–318
Calf muscle pump function
validation, chronic venous insufficiency 483–488
Cancer
eicosanoid production 264–266
Helicobacter pylori, serology 219–223
Capillaroscopy
microcirculation 131–139*
Capsaicin
chilli, stomach 252–254
Carbon dioxide
inspiratory effort sensation, sustained loading 513–518
recovery 665–677
Cardiac muscle
nutritional iron deficiency 233–239
Cardiac oxygenation
ischaemia, spectrophotometry 51–58
Catalase
diabetes 441–448
Catecholamines
adipose tissue, microdialysis 425–430
Cell adhesion
epidermal stem cells, integrins 141–146*
Cell adhesion molecules
  integrins 639–650*
Cell differentiation
  epidermal stem cells 141–146*
Cell division
  epidermal stem cells 141–146*
Cell proliferation
  epidermal growth factor, gastrointestinal tract 503–507
Cerebral blood supply
  hypertension 539–550
Cerebrovascular disease
  hypertension 539–550
Cervical carcinoma
  DNA testing, papillomavirus 250–252
Chemiluminescence
  oxidants, calcium antagonist 459–466
Chemoreceptors
  heart failure, heart rate variability 391–398
Chilli
  capsaicin, stomach 252–254
Cholecystokinin 8
  intracellular calcium, pancreatitis 365–369, 771
Cholesterol
  coronary heart disease, lipids 399–413, 773–774
Cholesterol metabolism
  creatine supplementation 113–118
Choline transport
  renal failure, haemodialysis 353–358
Chronic kidney failure
  body composition 763–769
Chronic venous insufficiency
  calf muscle pump function, validation 483–488
Cirrhosis
  tumour necrosis factor-α, pentoxifylline 29–33
Clinical research
  progress in Singapore 247–266
Colonic mucin
  corticosteroids, nicotine 359–364
Contractile response
  portal hypertension, octreotide 601–606
Contractility
  cardiac muscle, nutritional iron deficiency 233–239
Control of breathing
  breath-holding time, dyspnoea 755–761
Coronary heart disease
  cholesterol, lipids 399–413, 773–774
Coronary risk
  lipids 399–413, 773–774
Corticosteroids
  mucin, colon 359–364
Creatine supplementation
  lipid metabolism 113–118
Crohn’s disease
  fatty acids, phospholipids 509–512
Cromakalim
  therapeutic targets 651–663*
CV-11974
  renal vasodilatation, spontaneously hypertensive rats 147–154
Cyclic AMP
  G-protein-linked receptors, adrenomedullin 3–16*, 525
  G-proteins, signal transduction 527–537*
  lymphocytes, noradrenaline 621–626
Cyclic GMP
  inhaled nitric oxide 225–231
  neutral endopeptidase, ventricular pacing 283–291
Cyclosporin A
  renal transplant recipients 489–496
Cytochrome aa3
  ischaemia, spectrophotometry 51–58
Cytochrome c oxidase
  muscle wasting, zymosan 475–481
Cytokine
  pentoxifylline, cirrhosis 29–33
Cytokines
  nutrients, inflammation 121–130*
Densitometry
  chronic kidney failure 763–769
Dermis
  α-adrenergic receptors, reflex sympathetic dystrophy 73–77
Diabetes
  endothelium, dyslipidaemia 567–573
  microcirculation 131–139*
  oxidative stress 441–448
  oxidative stress, glyoxylase 575–582
Diabetes mellitus
  baroreflex sensitivity, autonomic function 59–64
Diabetic foot
  skin microcirculation, neuropathy 559–565
Diaphragm
  almitrine, electromyography 337–345
Diclofenac sodium
  nephrotoxicity, gentamicin 187–191
DNA testing
  papillomavirus, cervical carcinoma 250–252
Dopamine
  5-hydroxytryptamine, renal sodium excretion 177–185
  renal transplant recipients, cyclosporin A 489–496
Dyslipidaemia
  diabetes, endothelium 567–573
Dyspnoea
control of breathing, breath-holding
  time 755–761

Echocardiography
  left ventricular function, hypertension 275–281

EEG arousal
  blood pressure, sleep 45–50

Eicosanoid production
  hypertension, cancer 264–266

Electromyography
  muscle activity, almitrine 337–345

Embryos
  blastocyst transfer, stem cell production 248–249

Endothelin
  salt, essential hypertension 293–298

Endothelin peptides
  human kidney 267–273*

Endothelin receptors
  human kidney 267–273*

Endothelium
  diabetes, dyslipidaemia 567–573
  phenylephrine, liver cirrhosis 733–738
  Syndrome X 739–743

Energy expenditure
  bicarbonate-urea method, human
  immunodeficiency virus infection 241–245

Epidermal growth factor
  cell proliferation, gastrointestinal tract 503–507

Epidermal stem cells
  cell adhesion, integrins 141–146*

Epidermis
  α-adrenergic receptors, reflex sympathetic
  dystrophy 73–77

Epilepsy
  genetic analysis 264–266

Erythropoietin dysregulation
  renal failure 258–260

Essential hypertension
  salt, adrenomedullin 293–298

Exercise
  ATP synthesis, obesity 691–702
  EXP 3174
    renal vasodilatation, spontaneously hypertensive
    rats 147–154

Familial hypokalaemic periodic paralysis
  sodium pump 261–264

Fatiguability
  cytochrome c oxidase, zymosan 475–481

Fatigue
  inspiratory effort sensation, CO2
  responsiveness 513–518

Fats
  inflammation, cytokines 121–130*

phospholipids, Crohn’s disease 509–512

Fetal programming
  maternal nutrition, hypertension 607–615

Fibroblasts
  intracellular pH, free cytosolic calcium 703–710

Fluidity
  Na+, K+-ATPase, gestational hypertension 719–723

Fluoxetine
  5-hydroxytryptamine, platelet aggregation 87–92

Forearm blood flow
  arterIALIZATION 65–71
  menstrual cycle 163–168

Free cytosolic calcium
  microalbuminuria, non-insulin-dependent diabetes 703–710

Frusemide
  sodium depletion 299–305

Gallbladder
  sodium/hydrogen exchanger, sodium absorption 209–212

Gastrointestinal tract
  cell proliferation, epidermal growth factor 503–507

Gene expression
  pancreatitis-associated protein, mouse intestine 213–218

Genetic analysis
  research in Singapore 264–266

Genetic polymorphism
  angiotensin-converting enzyme, bradykinin 617–620

Geniohyoid
  almitrine, electromyography 337–345

Genomic
  nephrotoxicity, non-steroidal anti-inflammatory drugs 187–191

Gestational age
  renin, kidney 169–175

Gestational hypertension
  Na+, K+-ATPase 719–723

Glomerular filtration rate
  renal transplant recipients, cyclosporin A 489–496

Glomerulonephritis
  IgA nephropathy 258–260

Glucocorticoids
  fetal programming, hypertension 607–615

Glucose transport
  sarcolemma, insulin 591–599
<table>
<thead>
<tr>
<th>Subject</th>
<th>Page Numbers</th>
</tr>
</thead>
<tbody>
<tr>
<td>Gludopa</td>
<td>177–185</td>
</tr>
<tr>
<td>renal metabolism</td>
<td></td>
</tr>
<tr>
<td>$\gamma$-L-Glutamyl-5-hydroxy-L-tryptophan renal metabolism</td>
<td>177–185</td>
</tr>
<tr>
<td>Glutathione</td>
<td></td>
</tr>
<tr>
<td>antioxidant, cytokines</td>
<td>121–130*</td>
</tr>
<tr>
<td>Glutathione peroxidase</td>
<td></td>
</tr>
<tr>
<td>diabetes</td>
<td>441–448</td>
</tr>
<tr>
<td>Glycogenolysis</td>
<td></td>
</tr>
<tr>
<td>exercise, obesity</td>
<td>691–702</td>
</tr>
<tr>
<td>Glyoxal</td>
<td></td>
</tr>
<tr>
<td>diabetes, oxidative stress</td>
<td>575–582</td>
</tr>
<tr>
<td>Glyoxylase</td>
<td></td>
</tr>
<tr>
<td>diabetes, oxidative stress</td>
<td>575–582</td>
</tr>
<tr>
<td>G-protein-linked receptors</td>
<td></td>
</tr>
<tr>
<td>adrenomedullin, cyclic AMP</td>
<td>3–16*, 525</td>
</tr>
<tr>
<td>G-proteins</td>
<td></td>
</tr>
<tr>
<td>signal transduction, adenylate cyclase</td>
<td>527–537*</td>
</tr>
<tr>
<td>Granulocyte activation</td>
<td></td>
</tr>
<tr>
<td>inflammatory disease</td>
<td>329–335</td>
</tr>
<tr>
<td>Granulocyte pool</td>
<td></td>
</tr>
<tr>
<td>$^{111}\text{In-}}^{99m\text{Tc}}$-labelled granulocytes, inflammatory disease</td>
<td>329–335</td>
</tr>
<tr>
<td>Grape juice</td>
<td></td>
</tr>
<tr>
<td>phenolic compounds, lipoprotein oxidation</td>
<td>449–458</td>
</tr>
<tr>
<td>Growth hormone</td>
<td></td>
</tr>
<tr>
<td>male infertility</td>
<td>254–256</td>
</tr>
<tr>
<td>Haemodialysis</td>
<td></td>
</tr>
<tr>
<td>blood transfusion</td>
<td>519–523</td>
</tr>
<tr>
<td>renal failure, choline transport</td>
<td>353–358</td>
</tr>
<tr>
<td>Haemodynamics</td>
<td></td>
</tr>
<tr>
<td>ischaemia, spectrophotometry</td>
<td>51–58</td>
</tr>
<tr>
<td>meal ingestion, insulin</td>
<td>415–423</td>
</tr>
<tr>
<td>neutral endopeptidase, ventricular pacing</td>
<td>283–291</td>
</tr>
<tr>
<td>pentoxifylline, cirrhosis</td>
<td>29–33</td>
</tr>
<tr>
<td>Heart failure</td>
<td></td>
</tr>
<tr>
<td>adrenomedullin</td>
<td>3–16*, 525</td>
</tr>
<tr>
<td>autonomic nervous system, spectral power</td>
<td>35–43</td>
</tr>
<tr>
<td>heart rate variability, autonomic nervous system</td>
<td>391–398</td>
</tr>
<tr>
<td>Heart rate</td>
<td></td>
</tr>
<tr>
<td>blood pressure, sleep</td>
<td>45–50</td>
</tr>
<tr>
<td>Heart rate variability</td>
<td></td>
</tr>
<tr>
<td>autonomic nervous system, spectral power</td>
<td>35–43</td>
</tr>
<tr>
<td>heart failure, autonomic nervous system</td>
<td>391–398</td>
</tr>
<tr>
<td>Poincaré plot, parasympathetic nervous system</td>
<td>201–208</td>
</tr>
<tr>
<td>Helicobacter pylori</td>
<td></td>
</tr>
<tr>
<td>serology, cancer</td>
<td>219–223</td>
</tr>
<tr>
<td>High-performance liquid chromatography</td>
<td>non-transferrin-bound iron, preterm</td>
</tr>
<tr>
<td>babies</td>
<td></td>
</tr>
<tr>
<td>Hip</td>
<td></td>
</tr>
<tr>
<td>bone-mineral density, postmenopausal women</td>
<td>307–312</td>
</tr>
<tr>
<td>Homocysteine</td>
<td></td>
</tr>
<tr>
<td>metabolism</td>
<td>79–86</td>
</tr>
<tr>
<td>Hormone replacement therapy</td>
<td></td>
</tr>
<tr>
<td>bone mineral density, postmenopausal women</td>
<td>307–312</td>
</tr>
<tr>
<td>Human immunodeficiency virus infection energy expenditure, bicarbonate-urea method</td>
<td>241–245</td>
</tr>
<tr>
<td>Human leucocyte antigens</td>
<td></td>
</tr>
<tr>
<td>nasopharyngeal carcinoma</td>
<td>256–258</td>
</tr>
<tr>
<td>5-Hydroxytryptamine</td>
<td></td>
</tr>
<tr>
<td>dopamine, renal sodium excretion</td>
<td>177–185</td>
</tr>
<tr>
<td>platelet aggregation, fluoxetine</td>
<td>87–92</td>
</tr>
<tr>
<td>Hyperglycaemia</td>
<td></td>
</tr>
<tr>
<td>insulin release, muscle strength</td>
<td>583–589</td>
</tr>
<tr>
<td>Hyperinsulinaemic euglycaemic clamp insulin sensitivity, arterialization</td>
<td>65–71</td>
</tr>
<tr>
<td>Hypertension</td>
<td></td>
</tr>
<tr>
<td>adrenomedullin</td>
<td>3–16*, 525</td>
</tr>
<tr>
<td>contractile response, octreotide</td>
<td>601–606</td>
</tr>
<tr>
<td>eicosanoid production</td>
<td>264–266</td>
</tr>
<tr>
<td>fetal programming, maternal nutrition</td>
<td>607–615</td>
</tr>
<tr>
<td>left ventricular function</td>
<td></td>
</tr>
<tr>
<td>echocardiography</td>
<td>275–281</td>
</tr>
<tr>
<td>microcirculation</td>
<td>131–139*</td>
</tr>
<tr>
<td>Na$^+$, K$^+$-ATPase, ouabain</td>
<td>497–502</td>
</tr>
<tr>
<td>oxidative metabolism, brain</td>
<td>539–550</td>
</tr>
<tr>
<td>renin, gestational age</td>
<td>169–175</td>
</tr>
<tr>
<td>salt, adrenomedullin</td>
<td>293–298</td>
</tr>
<tr>
<td>salt sensitivity</td>
<td>155–161</td>
</tr>
<tr>
<td>Hyperventilation</td>
<td></td>
</tr>
<tr>
<td>alkalosis, magnesium</td>
<td>347–351</td>
</tr>
<tr>
<td>Hypokalaemic periodic paralysis</td>
<td></td>
</tr>
<tr>
<td>insulin release</td>
<td>583–589</td>
</tr>
<tr>
<td>sodium pump</td>
<td>261–264</td>
</tr>
<tr>
<td>Hypometabolism</td>
<td></td>
</tr>
<tr>
<td>amino acids, anaesthesia</td>
<td>431–439</td>
</tr>
<tr>
<td>Hypotension</td>
<td></td>
</tr>
<tr>
<td>stroke volume, syncope</td>
<td>193–200</td>
</tr>
<tr>
<td>Hypothermia</td>
<td></td>
</tr>
<tr>
<td>$\alpha$-adrenoceptor antagonist</td>
<td>627–631</td>
</tr>
<tr>
<td>amino acids, anaesthesia</td>
<td>431–439</td>
</tr>
<tr>
<td>Hypothermic preservation</td>
<td></td>
</tr>
<tr>
<td>rat heart, protein kinase C inhibitors</td>
<td>745–754</td>
</tr>
<tr>
<td>Hypoxia</td>
<td></td>
</tr>
<tr>
<td>pancreatitis-associated protein messenger RNA</td>
<td>213–218</td>
</tr>
<tr>
<td>Ibuprofen</td>
<td></td>
</tr>
<tr>
<td>nephrotoxicity, gentamicin</td>
<td>187–191</td>
</tr>
<tr>
<td>IgA nephropathy</td>
<td></td>
</tr>
</tbody>
</table>
Subject Index

primary glomerulonephritis 258–260

Immune complex disease
   inflammation mediators, nitric oxide 375–384*

Immunity
   nitric oxide 375–384*

Immunostaining
   mast cells, lung transplantation 319–327

   \textsuperscript{111}In-\textsuperscript{99mTc} labelled granulocytes
   lung granulocyte pool, inflammatory disease 329–335

Infertility
   growth hormone 254–256

Inflammation
   nutrients, cytokines 121–130*

Inflammation mediators
   nitric oxide, immune complex disease 375–384*

Inflammatory disease
   granulocyte activation, lung granulocyte pool 329–335

Inhaled nitric oxide
   platelet function 225–231

Innervation
   lung transplantation 319–327

Inspiratory effort sensation
   \textsuperscript{CO}_2 responsiveness, sustained loading 513–518

Insulin
   adipose tissue blood flow 679–683
   glucose transport, sarcolemma 591–599
   microalbuminuria, non-insulin-dependent diabetes 703–710
   regional haemodynamics, meal ingestion 415–423

Insulin release
   hypokalaemic periodic paralysis 583–589

Insulin sensitivity
   arterialization 65–71

Insulin-dependent diabetes mellitus
   baroreflex sensitivity, autonomic function 59–64

Integrins
   cell adhesion, epidermal stem cells 141–146*
   cell adhesion molecules 639–650*

Interleukin
   blood transfusion 519–523
   nutrients, inflammation 121–130*

Intracellular calcium
   pancreatitis 365–369, 771

Intracellular pH
   microalbuminuria, non-insulin-dependent diabetes 703–710

Intravenous nutrition
   epidermal growth factor 503–507

Intravital microscopy
   microcirculation 131–139*

Inulin clearance

   \textsuperscript{15}O
   menstrual cycle 163–168

Iron deficiency
   pancreatitis-associated protein messenger RNA 213–218

Iron overload
   pancreatitis-associated protein messenger RNA 213–218

Ischaemia
   cardiac oxygenation, spectrophotometry 51–58
   oxidants, calcium antagonist 459–466

   Iso-electric focusing
   serology, cancer 219–223

Iso-prostane
   lipid peroxidation, pregnancy 711–718

Keratinocytes
   epidermal stem cells 141–146*

Kidney
   endotheilns 267–273*
   fetal programming, hypertension 607–615
   renin, gestational age 169–175

Labelled carbon dioxide
   recovery 665–77

Left ventricular function
   echocardiography, hypertension 275–281

Lipid
   neutrophils, sepsis 371–374

   Lipid metabolism
   creatinine supplementation 113–118

Lipid peroxidation
   diabetes 441–448
   pre-eclampsia, pregnancy 711–718
   vitamin E, smoking 107–111

Lipids
   coronary heart disease, cholesterol 399–413,
   773–774

Lipoprotein oxidation
   phenolic compounds, wine 449–458

Lithium clearance
   renal transplant recipients, cyclosporin A 489–496

Liver
   autoimmunity, T-lymphocytes 551–558

   Liver cirrhosis
   phenylephrine, nitric oxide 733–738

   Loop of Henle
   sodium depletion, frusemide 299–305

   Loss of label
   carbon dioxide 665–677

   Lung granulocyte pool
   \textsuperscript{111}In-\textsuperscript{99mTc} labelled granulocytes, inflammatory disease 329–335

   Lung transplantation
   mast cells, bronchial hyper-responsiveness 319–327

   Lymphocytes
   cyclic AMP, noradrenaline 621–626
   protein synthesis, stable isotope 99–106
Magnesium
  alkalosis, hyperventilation 347–351
Magnetic resonance spectroscopy
  ATP synthesis 691–702
Male infertility
  growth hormone 254–256
Mast cells
  lung transplantation, bronchial
    hyper-responsiveness 319–327
Maternal nutrition
  fetal programming, hypertension 607–615
Meal ingestion
  regional haemodynamics, insulin 415–423
Mean arterial pressure
  metabolic risk factors, sex 385–389
Membrane
  sarcolemma, glucose transport 591–599
Membrane current
  cardiac muscle, nutritional iron
    deficiency 233–239
Menstrual cycle
  sex hormones, vascular relaxation 163–168
Mesenteric artery
  contractile response, octreotide 601–606
Messenger RNA
  pancreatitis-associated protein, mouse
    intestine 213–218
Metabolic risk factors
  blood pressure, sex 385–389
Metabolism
  amino acids, vascular disease 79–86
  thermoregulation, \( \alpha \)-adrenoceptor
    antagonist 627–631
Methodology
  labelled carbon dioxide, recovery 665–677
Methylglyoxal
  diabetes, oxidative stress 575–582
5-Methyltetrahydrofolate
  metabolism 79–86
Microalbuminuria
  intracellular pH, free cytosolic calcium 703–710
Microcirculation
  cardiovascular disease 131–139*
  diabetic foot, neuropathy 559–565
Microdialysis
  adipose tissue, catecholamines 425–430
Microperfusion
  loop of Henle, frusemide 299–305
Micropuncture
  sodium depletion, frusemide 299–305
Mineral water
  calcium nephrolithiasis 313–318
Mitochondria
  ischaemia, spectrophotometry 51–58
Morphology
  artery, Syndrome X 739–743
Mouse intestine
  pancreatitis-associated protein, messenger RNA 213–218
Mucin
  corticosteroids, nicotine 359–364
Multidrug resistance
  antisense oligodeoxynucleotides 93–98
Muscle
  oestrogen replacement therapy 685–690
  metabolism
    exercise, obesity 691–702
  strength
    hypokalaemic periodic paralysis 583–589
  wasting
    cytochrome c oxidase, zymosan 475–481
Myocardial infarction
  cholesterol, lipids 399–413, 773–774
Na\(^+\)/K\(^+\)/2Cl\(^–\) co-transport
  platelets 725–731
Na\(^+\), K\(^+\)-ATPase
  gestational hypertension 719–723
  ouabain, hypertension 497–502
Nasopharyngeal carcinoma
  human leucocyte antigens 256–258
Natriuresis
  adrenomedullin 3–16*, 525
  neutral endopeptidase, ventricular
    pacing 283–291
Natriuretic peptides
  neutral endopeptidase, ventricular
    pacing 283–291
Natural killer cells
  thyroid hormone, thyrotrophin 621–626
Nephrotoxicity
  gentamicin, non-steroidal anti-inflammatory
    drugs 187–191
Neuropathy
  diabetic foot, skin microcirculation 559–565
Neutral endopeptidase
  natriuretic peptides, ventricular pacing 283–291
Neutrophils
  total parenteral nutrition, sepsis 371–374
Nicotine
  mucin, colon 359–364
Nitric oxide
  alcoholic cirrhosis 23–28
  diabetes, dyslipidaemia 567–573
  immunity 375–384*
  phenylephrine, liver cirrhosis 733–738
  platelet function 225–231
Nitric oxide synthase
  immunity 375–384*
Non-insulin-dependent diabetes
  intracellular pH, free cytosolic calcium 703–710
Non-steroidal anti-inflammatory drugs
  nephrotoxicity, gentamicin 187–191
Non-transferrin-bound iron
  high-performance liquid chromatography, preterm
    babies 633–638
Noradrenaline
  lymphocytes, cyclic AMP 621–626
<table>
<thead>
<tr>
<th>Subject Index</th>
</tr>
</thead>
<tbody>
<tr>
<td>Salt sensitivity, hypertension</td>
</tr>
<tr>
<td><strong>Nutrients</strong></td>
</tr>
<tr>
<td>Inflammation, cytokines</td>
</tr>
<tr>
<td>Nutritional iron deficiency</td>
</tr>
<tr>
<td>Cardiac muscle</td>
</tr>
<tr>
<td>Adipose tissue blood flow</td>
</tr>
<tr>
<td>ATP synthesis, exercise</td>
</tr>
<tr>
<td>Octreotide</td>
</tr>
<tr>
<td>Contractile response, portal hypertension</td>
</tr>
<tr>
<td>Oestrogen replacement therapy muscle, balance</td>
</tr>
<tr>
<td>Ouabain</td>
</tr>
<tr>
<td>Na+, K+-ATPase, hypertension</td>
</tr>
<tr>
<td>Oxidants</td>
</tr>
<tr>
<td>Oxidation exercise, obesity</td>
</tr>
<tr>
<td>Oxidative metabolism</td>
</tr>
<tr>
<td>Oxidative stress diabetes</td>
</tr>
<tr>
<td>Diabetes</td>
</tr>
<tr>
<td>Oxygen consumption</td>
</tr>
<tr>
<td>Pancreatic acinar cells</td>
</tr>
<tr>
<td>Intracellular calcium, pancreatitis</td>
</tr>
<tr>
<td>Pancreatitis</td>
</tr>
<tr>
<td>Pancreatitis-associated protein messenger RNA, mouse intestine</td>
</tr>
<tr>
<td>Papillomavirus</td>
</tr>
<tr>
<td>DNA testing, cervical carcinoma</td>
</tr>
<tr>
<td>Parathyroid hormone, clear cell</td>
</tr>
<tr>
<td>Parasympathetic nervous system</td>
</tr>
<tr>
<td>Parenteral nutrition</td>
</tr>
<tr>
<td>Epidermal growth factor</td>
</tr>
<tr>
<td>Pentoxifylline</td>
</tr>
<tr>
<td>Tumour necrosis factor-α, cirrhosis</td>
</tr>
<tr>
<td>Phagocytosis</td>
</tr>
<tr>
<td>Phenolic compounds</td>
</tr>
<tr>
<td>Lipoprotein oxidation, wine</td>
</tr>
<tr>
<td>Phenolamine</td>
</tr>
<tr>
<td>Thermoregulation</td>
</tr>
<tr>
<td>Phenylephrine</td>
</tr>
<tr>
<td>Contractile response, octreotide</td>
</tr>
<tr>
<td>Nitric oxide, liver cirrhosis</td>
</tr>
<tr>
<td>Phosphocreatine breakdown</td>
</tr>
<tr>
<td>Exercise, obesity</td>
</tr>
<tr>
<td>Phospholipids</td>
</tr>
<tr>
<td>Fatty acids, Crohn’s disease</td>
</tr>
<tr>
<td>Physical activity</td>
</tr>
<tr>
<td>Bicarbonate-urea method, human immunodeficiency virus infection</td>
</tr>
<tr>
<td>Physical fitness</td>
</tr>
<tr>
<td>Pinacidil</td>
</tr>
<tr>
<td>Placenta</td>
</tr>
<tr>
<td>Platelet aggregation</td>
</tr>
<tr>
<td>Inhaled nitric oxide</td>
</tr>
<tr>
<td>Platelets</td>
</tr>
<tr>
<td>Oestrogen replacement therapy muscle, balance</td>
</tr>
<tr>
<td>Poincaré plot, heart rate variability</td>
</tr>
<tr>
<td>Polymerase chain reaction</td>
</tr>
<tr>
<td>Renal endothelins</td>
</tr>
<tr>
<td>Portocaval shunt</td>
</tr>
<tr>
<td>Postmenopausal women</td>
</tr>
<tr>
<td>Bone mineral density</td>
</tr>
<tr>
<td>Posture</td>
</tr>
<tr>
<td>Potassium</td>
</tr>
<tr>
<td>Potassium channel openers</td>
</tr>
<tr>
<td>Pre-eclampsia</td>
</tr>
<tr>
<td>Pregnancy</td>
</tr>
<tr>
<td>Pressure natriuresis</td>
</tr>
<tr>
<td>Non-transferrin-bound iron, high-performance liquid chromatography</td>
</tr>
<tr>
<td>Primary prevention</td>
</tr>
<tr>
<td>Protease</td>
</tr>
<tr>
<td>Rat heart, hypothermic preservation</td>
</tr>
<tr>
<td>Protein synthesis</td>
</tr>
<tr>
<td>Metabolic risk factors, sex</td>
</tr>
<tr>
<td>Rat heart</td>
</tr>
<tr>
<td>Hypothermic preservation, protein kinase C inhibitors</td>
</tr>
<tr>
<td>Recovery</td>
</tr>
</tbody>
</table>
labelled carbon dioxide 665–677
Reflex sympathetic dystrophy
\( \alpha \)-adrenergic receptors, skin 73–77
Renal endotoxins
quantitative polymerase chain reaction
analysis 267–273*
Renal failure
choline transport, haemodialysis 353–358
erythropoietin dysregulation 258–260
Renal plasma flow
renal transplant recipients, cyclosporin A 489–496
Renal sodium excretion
dopamine, 5-hydroxytryptamine 177–185
Renal transplant recipients
amino acids, dopamine 489–496
Renal tubule
sodium depletion, frusemide 299–305
Renal vasodilatation
angiotensin type 1 receptor antagonists, spontaneously hypertensive rats 147–154
Renin
gestational age, kidney 169–175
Renin–aldosterone axis
salt sensitivity, hypertension 155–161
Resistance arteries
nitric oxide, alcoholic cirrhosis 23–28
Respiratory frequency
spectral power 35–43
Salt
adrenomedullin, essential hypertension 293–298
Salt sensitivity
hypertension 155–161
Sarcolemma
glucose transport, insulin 591–599
Schizophrenia
genetic analysis 264–266
Secondary prevention
coronary heart disease 399–413, 773–774
Sepsis
neutrophils, total parenteral nutrition 371–374
Serology
*Helicobacter pylori*, cancer 219–223
Sex
metabolic risk factors, blood pressure 385–389
Sex hormones
menstrual cycle, vascular relaxation 163–168
Signal transduction
G-proteins, adenylate cyclase 527–537*
Singapore
genetic studies 264–266
progress in clinical research 247–266
Skeletal muscle blood flow
meal ingestion, insulin 415–423
Skin
\( \alpha \)-adrenergic receptors, reflex sympathetic dystrophy 73–77
Skin fibroblasts
intracellular pH, free cytosolic calcium 703–710
Skin microcirculation
diabetic foot, neuropathy 559–565
menstrual cycle 163–168
Sleep
blood pressure, ambulatory monitoring 45–50
Smoking
antioxidant enzyme, vitamin E 107–111
lymphocytes, cyclic AMP 621–626
Smooth muscle
nitric oxide, alcoholic cirrhosis 23–28
Sodium absorption
gallbladder, sodium/hydrogen exchanger 209–212
Sodium clearance
renal transplant recipients, cyclosporin A 489–496
Sodium depletion
frusemide 299–305
Sodium/hydrogen exchanger
gallbladder, sodium absorption 209–212
Sodium pump
hypokalaemic periodic muscle paralysis 261–264
Spectral power
autonomic nervous system, heart failure 35–43
Spectrophotometry
cardiac oxygenation, ischaemia 51–58
Spermatogenesis
growth factors 254–256
Spine
bone mineral density, postmenopausal women 307–312
Spiral laminar flow
vascular disease, ultrasound 17–21
Splanchnic oxygen uptake
amino acids, anaesthesia 431–439
Spontaneously hypertensive rats
oxidative metabolism, brain 539–550
renal vasodilatation, angiotensin type 1 receptor antagonists 147–154
Stable isotope
lymphocytes, protein synthesis 99–106
Stem cell production
human embryos 248–249
Stomach
chilli, capsaicin 252–254
Stroke
cholesterol, lipids 399–413, 773–774
Stroke volume
blood pressure, syncope 193–200
Subcellular fractionation
muscle wasting, zymosan 475–481
Sudden death
baroreflex sensitivity, insulin-dependent diabetes mellitus 59–64
Superoxide dismutase
diabetes 441–448
Surgery
Subject Index

lymphocytes, protein synthesis 99–106
Sustained loading
  inspiratory effort sensation, CO₂ responsiveness 513–518
Sympathetic nervous system
  blood pressure, sleep 45–50
Sympathetic nervous system
  blood pressure, stroke volume 193–200
Syndrome X
  artery, morphology 739–743
T-cell receptor genes
  nasopharyngeal carcinoma 256–258
T-helper 2 cytokines
  blood transfusion 519–523
T-lymphocytes
  autoimmunity, biliary cirrhosis 551–558
Therapeutic targets
  potassium channel openers 651–663*
Thermogenesis
  amino acids, anaesthesia 431–439
Thermoregulation
  α-adrenoceptor antagonist 627–631
Thyroid hormones
  cardiac muscle, nutritional iron deficiency 233–239
  thyrotoxic periodic paralysis
  sodium pump 261–264
Tissue repair
  lung transplantation 319–327
Tolerance
  T-lymphocytes, biliary cirrhosis 551–558
Total body water
  chronic kidney failure 763–769
Total parenteral nutrition
  neutrophils, sepsis 371–374
Transforming growth factor
  blood transfusion 519–523
Triacylglycerol metabolism
  creatine supplementation 113–118
Tryptophan
  Na⁺, K⁺-ATPase, gestational hypertension 719–723
Tubular function
  renal transplant recipients, cyclosporin A 489–496
Tumour necrosis factor
  nutrients, inflammation 121–130*
  pentoxifylline, cirrhosis 29–33

Tumour suppressor gene
  nasopharyngeal carcinoma 256–258
Ultrasound
  blood flow, vascular disease 17–21
Urinary bladder
  calcium antagonist 467–474
Urine state of saturation
  calcium nephrolithiasis, mineral water 313–318
Urogastrone
  cell proliferation, gastrointestinal tract 503–507
Vascular disease
  blood flow, ultrasound 17–21
  metabolism, amino acids 79–86
Vascular relaxation
  sex hormones, menstrual cycle 163–168
  Vascular tone
  menstrual cycle 163–168
Vasoconstriction
  thermoregulation, α-adrenoceptor antagonist 627–631
Vasodilatation
  diabetes, dyslipidaemia 567–573
Vasodilator peptides
  adrenomedullin 3–16*, 525
Vasopressin
  contractile response, octreotide 601–606
Veins
  nitric oxide, alcoholic cirrhosis 23–28
Ventilation
  almitrine 337–345
Ventricular pacing
  natriuretic peptides, neutral endopeptidase 283–291
Vitamin E
  antioxidant enzyme, smoking 107–111
  inflammation, cytokines 121–130*
White-coat hypertension
  left ventricular function, echocardiography 275–281
Wine
  phenolic compounds, lipoprotein oxidation 449–458
X-ray absorptiometry
  chronic kidney failure 763–769
Zymosan
  muscle wasting, cytochrome c oxidase 475–481